

Jameel M Inal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5841341/publications.pdf>

Version: 2024-02-01

65
papers

11,037
citations

126907

33
h-index

118850

62
g-index

67
all docs

67
docs citations

67
times ranked

16353
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	12.2	6,961
2	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. <i>PLoS Biology</i> , 2012, 10, e1001450.	5.6	1,064
3	EVpedia: a community web portal for extracellular vesicles research. <i>Bioinformatics</i> , 2015, 31, 933-939.	4.1	317
4	Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 27522.	12.2	228
5	<i>Trypanosoma cruzi</i> Immune Evasion Mediated by Host Cell-Derived Microvesicles. <i>Journal of Immunology</i> , 2012, 188, 1942-1952.	0.8	139
6	Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1007.	4.1	132
7	A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26192.	12.2	126
8	A filtration-based protocol to isolate human Plasma Membrane-derived Vesicles and exosomes from blood plasma. <i>Journal of Immunological Methods</i> , 2011, 371, 143-151.	1.4	115
9	Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 889.	3.5	115
10	Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo. <i>Scientific Reports</i> , 2015, 5, 13006.	3.3	88
11	Blood/plasma secretome and microvesicles. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2317-2325.	2.3	87
12	Role of early lectin pathway activation in the complement-mediated killing of <i>Trypanosoma cruzi</i> . <i>Molecular Immunology</i> , 2009, 47, 426-437.	2.2	82
13	Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. <i>Clinical Science</i> , 2020, 134, 1301-1304.	4.3	75
14	Microvesicles released from <i>Giardia intestinalis</i> disturb host-pathogen response in vitro. <i>European Journal of Cell Biology</i> , 2017, 96, 131-142.	3.6	72
15	Peptidylarginine Deiminases Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1196.	4.1	70
16	The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. <i>International Journal of Cancer</i> , 2017, 141, 428-436.	5.1	67
17	Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 324.	3.9	63
18	Peptidylarginine Deiminases Post-Translationally Deiminate Prohibitin and Modulate Extracellular Vesicle Release and MicroRNAs in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2019, 20, 103.	4.1	63

#	ARTICLE	IF	CITATIONS
19	Peptidylarginine Deiminase Inhibitors Reduce Bacterial Membrane Vesicle Release and Sensitize Bacteria to Antibiotic Treatment. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 227.	3.9	61
20	Microvesicles in Health and Disease. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 107-121.	2.3	59
21	Phage therapy: a reappraisal of bacteriophages as antibiotics. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2003, 51, 237-44.	2.3	59
22	Mesenchymal Stromal Cell Derived Extracellular Vesicles Reduce Hypoxia-Ischaemia Induced Perinatal Brain Injury. <i>Frontiers in Physiology</i> , 2019, 10, 282.	2.8	57
23	Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells. <i>Translational Oncology</i> , 2019, 12, 513-522.	3.7	55
24	Human Plasma Membrane-Derived Vesicles Halt Proliferation and Induce Differentiation of THP-1 Acute Monocytic Leukemia Cells. <i>Journal of Immunology</i> , 2010, 185, 5236-5246.	0.8	54
25	Human plasma membrane-derived vesicles inhibit the phagocytosis of apoptotic cells – Possible role in SLE. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 278-283.	2.1	51
26	Complement C2 Receptor Inhibitor Trispanning: A Novel Human Complement Inhibitory Receptor. <i>Journal of Immunology</i> , 2005, 174, 356-366.	0.8	46
27	Complement Mediates the Binding of HIV to Erythrocytes. <i>Journal of Immunology</i> , 2004, 173, 4236-4241.	0.8	45
28	Peptidylarginine Deiminase Isozyme-Specific PAD2, PAD3 and PAD4 Inhibitors Differentially Modulate Extracellular Vesicle Signatures and Cell Invasion in Two Glioblastoma Multiforme Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1495.	4.1	43
29	Complement C2 Receptor Inhibitor Trispanning and the β -Chain of C4 Share a Binding Site for Complement C2. <i>Journal of Immunology</i> , 2002, 168, 5213-5221.	0.8	42
30	The role of microvesicles in cancer progression and drug resistance. <i>Biochemical Society Transactions</i> , 2013, 41, 293-298.	3.4	36
31	Interplay of host-pathogen microvesicles and their role in infectious disease. <i>Biochemical Society Transactions</i> , 2013, 41, 258-262.	3.4	36
32	Coxsackievirus B transmission and possible new roles for extracellular vesicles. <i>Biochemical Society Transactions</i> , 2013, 41, 299-302.	3.4	35
33	ASchistosomaprotein, Sh-TOR, is a novel inhibitor of complement which binds human C2. <i>FEBS Letters</i> , 2000, 470, 131-134.	2.8	34
34	Complement C2 Receptor Inhibitor Trispanning Confers an Increased Ability to Resist Complement-Mediated Lysis in <i>Trypanosoma cruzi</i> . <i>Journal of Infectious Diseases</i> , 2008, 198, 1276-1283.	4.0	34
35	Involvement of lectin pathway activation in the complement killing of <i>Giardia intestinalis</i> . <i>Biochemical and Biophysical Research Communications</i> , 2010, 395, 382-386.	2.1	34
36	Communication is key: extracellular vesicles as mediators of infection and defence during host-microbe interactions in animals and plants. <i>FEMS Microbiology Reviews</i> , 2022, 46, .	8.6	33

#	ARTICLE	IF	CITATIONS
37	Red cell PMVs, plasma membrane-derived vesicles calling out for standards. <i>Biochemical and Biophysical Research Communications</i> , 2010, 399, 465-469.	2.1	29
38	Pulsed extremely low-frequency magnetic fields stimulate microvesicle release from human monocytic leukaemia cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 430, 470-475.	2.1	27
39	Plasma mEV levels in Ghanaian malaria patients with low parasitaemia are higher than those of healthy controls, raising the potential for parasite markers in mEVs as diagnostic targets. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1697124.	12.2	24
40	Ït20, A Temperate Bacteriophage Isolated from <i>Bacillus anthracis</i> Exists as a Plasmidial Prophage. <i>Current Microbiology</i> , 1996, 32, 171-175.	2.2	23
41	Schistosoma TOR (trispinning orphan receptor), a novel, antigenic surface receptor of the blood-dwelling, Schistosoma parasite. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1445, 283-298.	2.4	22
42	The complement inhibitor, CRIT, undergoes clathrin-dependent endocytosis. <i>Experimental Cell Research</i> , 2005, 310, 54-65.	2.6	21
43	A new landscape of host-protozoa interactions involving the extracellular vesicles world. <i>Parasitology</i> , 2018, 145, 1521-1530.	1.5	18
44	A Peptide Derived from the Parasite Receptor, Complement C2 Receptor Inhibitor Trispinning, Suppresses Immune Complex-Mediated Inflammation in Mice. <i>Journal of Immunology</i> , 2003, 170, 4310-4317.	0.8	17
45	Complement C2 receptor inhibitor trispinning: from man to schistosome. <i>Seminars in Immunopathology</i> , 2005, 27, 320-331.	4.0	17
46	Parasite interaction with host complement: beyond attack regulation. <i>Trends in Parasitology</i> , 2004, 20, 407-412.	3.3	15
47	Prostate cancer cells stimulated by calcium-mediated activation of protein kinase C undergo a refractory period before re-releasing calcium-bearing microvesicles. <i>Biochemical and Biophysical Research Communications</i> , 2015, 460, 511-517.	2.1	15
48	Microvesicles released constitutively from prostate cancer cells differ biochemically and functionally to stimulated microvesicles released through sublytic C5b-9. <i>Biochemical and Biophysical Research Communications</i> , 2015, 460, 589-595.	2.1	14
49	COVID-19 comorbidities, associated procoagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity?. <i>British Journal of Haematology</i> , 2020, 190, e218-e220.	2.5	14
50	Complement inhibition in renal diseases. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 237-240.	0.7	13
51	Sequence and immunogenicity of the 23-kDa transmembrane antigen of <i>Schistosoma haematobium</i> . <i>Molecular and Biochemical Parasitology</i> , 1995, 74, 217-221.	1.1	12
52	Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT. <i>Biochemical Journal</i> , 2005, 389, 863-868.	3.7	11
53	Label-free real-time acoustic sensing of microvesicle release from prostate cancer (PC3) cells using a Quartz Crystal Microbalance. <i>Biochemical and Biophysical Research Communications</i> , 2014, 453, 619-624.	2.1	11
54	Microvesiculation and Disease. <i>Biochemical Society Transactions</i> , 2013, 41, 237-240.	3.4	10

#	ARTICLE	IF	CITATIONS
55	Complement-mediated Extracellular Vesicle release as a measure of endothelial dysfunction and prognostic marker for COVID-19 in peripheral blood - Letter to the Editor. <i>Clinical Hemorheology and Microcirculation</i> , 2020, 75, 383-386.	1.7	9
56	Biological Factors Linking ApoE Îµ4 Variant and Severe COVID-19. <i>Current Atherosclerosis Reports</i> , 2020, 22, 70.	4.8	8
57	CRIT peptide interacts with factor B and interferes with alternative pathway activation. <i>Biochemical and Biophysical Research Communications</i> , 2006, 344, 308-314.	2.1	7
58	CRIT is expressed on podocytes in normal human kidney and upregulated in membranous nephropathy. <i>Kidney International</i> , 2006, 69, 1961-1968.	5.2	6
59	Prostate cancer and microfluids. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 455-470.	1.6	6
60	Generalized transduction in <i>Bacillus thuringiensis</i> var. <i>aizawai</i> . <i>Journal of Applied Bacteriology</i> , 1992, 72, 87-90.	1.1	3
61	<i>Bacillus thuringiensis</i> subsp. <i>aizawai</i> generalized transducing phage 4HD248 : restriction site map and potential for fine-structure chromosomal mapping. <i>Microbiology (United Kingdom)</i> , 1996, 142, 1409-1416.	1.8	3
62	Microfabrication of conical microfunnels for drug delivery applications. <i>Micro and Nano Letters</i> , 2015, 10, 355-357.	1.3	1
63	The complement regulatory receptor CRIT is expressed in the developing kidney. <i>Molecular Immunology</i> , 2007, 44, 3991.	2.2	0
64	The intracellular <i>Trypanosoma cruzi</i> induces the release from monocytes of plasma membrane-derived microvesicles which protect the parasite from host complement. <i>Molecular Immunology</i> , 2008, 45, 4173.	2.2	0
65	Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology. , 2017, , 413-425.		0